|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
WLY016594924 |
| 003 |
DE-627 |
| 005 |
20231111193111.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231111s2023 xx |||||o 00| ||und c |
| 024 |
7 |
|
|a 10.1111/pim.12948
|2 doi
|
| 028 |
5 |
2 |
|a 2023-11-11_PIM_2023_45_2.zip.xml
|
| 035 |
|
|
|a (DE-627)WLY016594924
|
| 035 |
|
|
|a (WILEY)PIM12948
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rda
|
| 100 |
1 |
|
|a Ruchti, Fiorella
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a New insights into immunity to skin fungi shape our understanding of health and disease
|
| 264 |
|
1 |
|c 2023
|
| 300 |
|
|
|a 11
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a © 2023 John Wiley & Sons Ltd.
|
| 520 |
|
|
|a Abstract Fungi represent an integral part of the skin microbiota. Their complex interaction network with the host shapes protective immunity during homeostasis. If host defences are breached, skin‐resident fungi including Malassezia and Candida, and environmental fungi such as dermatophytes can cause cutaneous infections. In addition, fungi are associated with diverse non‐infectious skin disorders. Despite their multiple roles in health and disease, fungi remain elusive and understudied, and the mechanisms underlying the emergence of pathological conditions linked to fungi are largely unclear. The identification of IL‐17 as an important antifungal effector mechanism represents a milestone for understanding homeostatic antifungal immunity. At the same time, host‐adverse, disease‐promoting roles of IL‐17 have been delineated, as in psoriasis. Fungal dysbiosis represents another feature of many pathological skin conditions with an unknown causal link of intra‐ and interkingdom interactions to disease pathogenesis. The emergence of new fungal pathogens such as Candida auris highlights the need for more research into fungal immunology to understand how antifungal responses shape health and diseases. Recent technological advances for genetically manipulating fungi to target immunomodulatory fungal determinants, multi‐omics approaches for studying immune cells in the human skin, and novel experimental models open up a promising future for skin fungal immunity.
|
| 700 |
1 |
|
|a LeibundGut‐Landmann, Salomé
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Parasite Immunology
|g 45(2023), 2
|w (DE-627)WLY012322709
|x 13653024
|7 nnns
|
| 773 |
1 |
8 |
|g volume:45
|g year:2023
|g number:2
|g extent:11
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_WLY
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_21
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_110
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_206
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_618
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2009
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 912 |
|
|
|a GBV_ILN_2035
|
| 912 |
|
|
|a GBV_ILN_2105
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 45
|j 2023
|e 2
|g 11
|